Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.64 USD
+0.04 (2.50%)
Updated May 2, 2024 03:59 PM ET
After-Market: $1.64 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MIST 1.64 +0.04(2.50%)
Will MIST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks
Other News for MIST
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
Milestone’s Etripamil Shows Promise in Self-Managed PSVT Treatment
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Milestone: Etripamil 'effective' at restoring sinus rhythm in trial